Short-term growth hormone treatment and microcirculation: Effects in patients with chronic kidney disease
| Autor: | Thomas Körber, Dieter Haffner, Dagmar-Christiane Fischer, Andreas Puhlmann, Michael Tieβ, Andrea Mitzner, Richard Nissel, Michael Petzsch, Reinhard Schmidt, Birgit Holdt-Lehmann |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male medicine.medical_specialty Cardiac output Cardiac index Pilot Projects Biochemistry Body Mass Index Microcirculation Internal medicine medicine Humans Plethysmograph Insulin-Like Growth Factor I Endothelial dysfunction Microscopy Video Human Growth Hormone business.industry Cell Biology Middle Aged medicine.disease Recombinant Proteins Plethysmography Growth hormone treatment Insulin-Like Growth Factor Binding Protein 3 Treatment Outcome medicine.anatomical_structure Endocrinology Echocardiography Regional Blood Flow Case-Control Studies Cardiology Vascular resistance Kidney Failure Chronic Female Cardiology and Cardiovascular Medicine business Kidney disease |
| Zdroj: | Microvascular Research. 78:246-252 |
| ISSN: | 0026-2862 |
| Popis: | Endothelial dysfunction is common in patients with chronic kidney disease (CKD) and contributes significantly to the high long-term cardiovascular morbidity and mortality. The short-term cardiovascular effects of recombinant human growth hormone (rhGH) in CKD patients (stages III–V) and healthy controls ( n = 15 each) were explored in a single-center, non-randomized pilot study. Subjects were investigated before, after a 7 day treatment with rhGH, and after a 7 day wash-out period. Microcirculation was assessed by nailfold capillaroscopy and leg strain gauge plethysmography. Echocardiography was performed and serum concentrations of IGF-I and IGF-binding protein-3 (IGFBP-3) were determined. Before the start of rhGH therapy, mean post-ischemic maximum flow velocity of erythrocytes ( V RBC ) and leg blood flow (LBF) in CKD patients were significantly reduced to 68% and 75% of that seen in controls, whereas V RBC and LBF under resting conditions were comparable. Treatment with rhGH significantly increased V RBC and LBF under resting conditions. Whereas maximum post-ischemic V RBC was improved by rhGH in patients and controls, maximum post-ischemic LBF increased in controls only. This was paralleled by a non-significant reduction of total vascular resistance, and increased heart rate and cardiac index. In conclusion, CKD patients respond to short-term rhGH treatment with significantly improved capillary blood flow, whereas only minor effects on total peripheral resistance and cardiac output were noted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect